ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients

Leukemia

Volumn 28, Issue 11, 2014, Pages 2206-2212

  Patnaik, M M ^a   Itzykson, R ^b,c,d   Lasho, T L ^a   Kosmider, O ^b,e   Finke, C M ^a   Hanson, C A ^a   Knudson, R A ^a   Ketterling, R P ^a   Tefferi, A ^a   Solary, E ^c,d,f  

^a MAYO CLINIC   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSTITUT COCHIN   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; POLYCOMB GROUP PROTEIN; ASXL1 PROTEIN, HUMAN; CARRIER PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SETBP1 PROTEIN, HUMAN; STOP CODON;

ADULT; AGED; ARTICLE; ASXL1 GENE; BONE MARROW CELL; BONE MARROW EXAMINATION; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; DNA DETERMINATION; FEMALE; FRAMESHIFT MUTATION; GENE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPHIL COUNT; NONSENSE MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; SETBP1 GENE; SPLICEOSOME; THROMBOCYTE COUNT; VERY ELDERLY; CLINICAL TRIAL; GENETIC SCREENING; GENETICS; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTOR; STATISTICAL MODEL; STOP CODON; SURVIVAL; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CODON, NONSENSE; FEMALE; FRAMESHIFT MUTATION; GENETIC TESTING; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PROGNOSIS; REPRESSOR PROTEINS; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84922332658     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.125     Document Type: Article

References (33)

1. Swederlow S, Campo E, Harris NL, Jaffe ES, Stefano PA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.
2. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol 2014;165:273-286.
3. Damm F, Itzykson R, Kosmider O, Droin N, Renneville A, Chesnais V et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013;27:1401-1403.
4. Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009;145:788-800.
5. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436.
6. Laborde R, Patnaik M, Lasho T, Finke C, Hanson C, Knudson R et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. Leukemia 2013;27:2100-2102.
7. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012;120:3080-3088.
8. Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011;25:1200-1202.
9. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013;45:18-24.
10. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013;27:1504-1510.
11. Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i (17) (q10), ASXL1 and CBL mutations. Leukemia 2013;27:1852-1860.
12. Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011;96:375-383.
13. Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002;99:840-849.
14. Lasho TL, Jimma T, Finke CM, Patnaik M, Hanson CA, Ketterling RP et al. SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood 2012;120:4168-4171.
15. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119:569-572.
16. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-69.
17. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-1138.
18. Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL. The most commonly reported variant in ASXL1 (c.1934dupG;p. Gly646TrpfsX12) is not a somatic alteration. Leukemia 2010;24:1656-1657.
19. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol 2012;5:12.
20. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011;29:2499-2506.
21. Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010;24:1062-1065.
22. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adelaide J, Rey J et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009;23:2183-2186.
23. Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adelaide J et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010;24:469-473.
24. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.
25. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013;27:1861-1869.
26. Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014;28:1494-1500.
27. Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One 2014;9:e85362.
28. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 2013;122:2460-2466.
29. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079-1089.
30. Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia 2013;27:82-91.
31. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011;118:5593-5603.
32. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011;118:6920-6929.
33. Tefferi A, Finke CM, Lasho TL, Wassie EA, Knudson R, Ketterling RP et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia 2014;28:431-433.